Comparison of Immune Response in Mice Immunized With Recombinant Pres2/S-C18-27 Protein Derived From Hepatitis B Virus With Commercial Vaccine

Background objective: the vaccine available to prevent hepatitis b virus disease is ineffective in 5% of people due to the use of hbsag as a weak immunogen. in the present study, pres2/s fused to c18-27 peptide fragment as an effective antigen and is proposed as a promising vaccine candidate compared with the conventional vaccine prescribed in the vaccination program.methods: after the synthesis of pres2/s genes and c18-27 peptide fragment in pet28a, the recombinant protein was confirmed by western blotting. the efficacy of the pres2/s-c18-27 protein was compared with the conventional vaccine injected into five groups of rats. finally, the cytokine level of if-r, il-2, il-4, il-10, tnf-a, igg1, and igg2a were measured using the elisa method.results: this study showed no significant difference between the recombinant vaccine group and pbs control group in the if-r test, but there was a significant difference between groups testing il-2 and il-10. in addition, the group receiving the recombinant vaccine with cpg adjuvant at a dilution of 1/10 in the igg total test on days 14 and 45 after the first injection showed a significant difference in comparison with other groups.conclusion: this study showed no statistically significant difference between the recombinant protein vaccine group and the conventional vaccine group. the th1- mediated immune responses obtained from recombinant proteins with and without cpg performed better than conventional vaccines, possibly due to the functional deficiency of the available vaccines.